Search
Lacosamide
go.drugbank.com/drugs/DB06218ApprovedInvestigationalLacosamide is an antiepileptic drug used to treat seizures. As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents.
Garetosmab
go.drugbank.com/drugs/DB16379ApprovedInvestigationalGaretosmab-grts is an activin A inhibitor used to treat fibrodysplasia ossificans progressiva (FOP).
Molybdenum
go.drugbank.com/drugs/DB11137ApprovedInvestigationalIt is an essential trace dietary element and acts as a critical cofactor in several molybdenum-dependent enzymes that are involved in important cellular reactions and pathways, including xanthine oxidoreductase
Mixtures: Liquid Opti-minplex +d, Iron 25mg With Vit B-cmplx, Vit C, Cu & MoTradipitant
go.drugbank.com/drugs/DB12580ApprovedInvestigationalTradipitant is a selective, high-affinity antagonist at human substance P/neurokinin-1 (NK-1) receptors. NK-1 receptors are expressed in the brainstem and nucleus tractus solitarius, which receives emetogenic signals from various stimuli...
Sodium molybdate
go.drugbank.com/drugs/DB14496ApprovedMixtures: GENERADOR DE SOLUCION INYECTABLE DE PERTECNETATO (99MTC) DE SODIO. 2-50GBQ, VINATAL DHA CAPSULA DE GELATINA BLANDAEsmolol
go.drugbank.com/drugs/DB00187ApprovedInvestigationalWithdrawnEsmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing acti...
Hydroxocobalamin
go.drugbank.com/drugs/DB00200ApprovedInvestigationalHydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is an injectable form of vitamin B 12 that has been used therapeutically to treat vitamin B 12 deficiency.
Mixtures: Escavite DProducts: VITAMIN B12 DEP PAN 1000UGKIN-3248
go.drugbank.com/drugs/DB17587InvestigationalKIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs). … [L45469] In February 2023, Kinnate Biopharma received Fast Track designation from the FDA for KIN-3248 to treat unresectable, locally advanced or metastatic cholangiocarcinoma (CCA).[L45474]
Sutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigational[A245159] Pharmacologic strategies have included the targeting of B-cells with agents like [rituximab], as well as targeting of the complement system with drugs like [eculizumab], an anti-C5 mAb, and [
Vonoprazan
go.drugbank.com/drugs/DB11739ApprovedInvestigationalUnlike proton-pump inhibitors, PCABs are not affected by CYP2C19 genetic polymorphisms and do not require acid-resistant formulations. … PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders.